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Performance Metrics in Professional Baseball
Pitchers before and after Surgical Treatment
for Neurogenic Thoracic Outlet Syndrome
Robert W. Thompson,1 Corey Dawkins,2 Chandu Vemuri,1 Michael W. Mulholland,3
Tyler D. Hadzinsky,4 and Gregory J. Pearl,5 St. Louis, Missouri, Waltham, Massachusetts,
Ann Arbor, Michigan, and Dallas, Texas
Background: High-performance throwing athletes may be susceptible to the development of
neurogenic thoracic outlet syndrome (NTOS). This condition can be career-threatening but
the outcomes of treatment for NTOS in elite athletes have not been well characterized. The pur-
pose of this study was to utilize objective performance metrics to evaluate the impact of surgical
treatment for NTOS in Major League Baseball (MLB) pitchers.
Methods: Thirteen established MLB pitchers underwent operations for NTOS between July
2001 and July 2014. For those returning to MLB, traditional and advanced (PitchF/x) MLB per-
formance metrics were acquired from public databases for various time-period scenarios before
and after surgery, with comparisons made using paired t-tests, Wilcoxon matched-pair signed-
rank tests, and KruskaleWallis analysis of variance.
Results: Ten of 13 pitchers (77%) achieved a sustained return to MLB, with a mean age of
30.2 ± 1.4 years at the time of surgery and 10.8 ± 1.5 months of postoperative rehabilitation
before the return to MLB. Pre- and postoperative career data revealed no significant differences
for 15 traditional pitching metrics, including earned run average (ERA), fielding independent
pitching, walks plus hits per inning pitched (WHIP), walks per 9 innings, and strikeouts to
walk ratio (SO/BB). There were also no significant differences between the 3 years before
and the 3 years after surgical treatment. Using PitchF/x data for 72 advanced metrics and 25
different time-period scenarios, the highest number of significant relationships (n ¼ 18) was
observed for the 8 weeks before/12 weeks after scenario. In this analysis, 54 (75%) measures
were unchanged (including ERA, WHIP, and SO/BB) and 14 (19%) were significantly improved,
while only 4 (6%) were significantly decreased (including hard pitch maximal velocity 93.1 ± 1.0
vs. 92.5 ± 0.9 miles/hr, P ¼ 0.047). Six pitchers remained active in MLB during the study period,
while the other 4 had retired due to factors or injuries unrelated to NTOS.
Conclusions: Objective performance metrics demonstrate that pitchers returning to MLB after
surgery for NTOS have had capabilities equivalent to or better than before treatment. Thoracic
outlet decompression coupled with an ample period of postoperative rehabilitation can provide
effective treatment for professional baseball pitchers with career-threatening NTOS.
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INTRODUCTION
Neurogenic thoracic outlet syndrome (NTOS) is a
rare and potentially disabling condition caused by
dynamic compression of the brachial plexus.1 It is
thought to be caused by predisposing variations in
anatomy combined with scalene and/or pectoralis
minor muscle hypertrophy or injury, resulting in
muscle fibrosis and excessive, sustained, muscle
spasm.1 Compression and irritation of the adjacent
brachial plexus is reflected by tenderness over the
scalene triangle and/or subcoracoid space, along
with exacerbation of upper extremity pain, numb-
ness, and paresthesia during arm elevation.2,3
Because there are no laboratory testing approaches,
electrophysiological tests, or imaging procedures
that are sufficiently accurate to establish or dismiss
NTOS, the diagnosis is based largely on the exclu-
sion of other conditions and a recognition of stereo-
typical clinical patterns.3 The initial treatment of
NTOS is almost always centered on pain manage-
ment, physical therapy, and workplace ergonomic
modifications, but surgical management is recom-
mended when there are disabling symptoms, a
sound clinical diagnosis, and a lack of satisfactory
improvement following conservative approaches.1,4
Recent studies indicate that there have been im-
provements in the outcome of surgical treatment for
NTOS, along with increasing evidence for enhanced
quality-of-life in surgical patients.4e7 The outcomes
of surgery for NTOS are usually measured in
conventional terms (postoperative complications,
hospital length of stay, etc.), as well as self-
assessment symptom surveys, validated measure-
ment instruments, and rates of return to work.4e7
However, such approaches may provide incomplete
assessment of results, given that patients recovered
from surgical treatment may still have intermittent
or activity-related symptoms. It is important to
continue developing new approaches to more accu-
rately assess the functional outcomes of surgical
treatment for NTOS.
High-performance throwing athletes may be sus-
ceptible to the development of NTOS as a manifesta-
tion of repetitive strain injury and this condition has
been occasionally identified in collegiate and profes-
sional baseball players.8e12 In elite athletes, NTOS
can be a career-threatening condition and surgical
treatment may often be recommended. While excel-
lent outcomes of surgical treatment have been
described for elite overhead athletes undergoing sur-
gical treatment for venous TOS (subclavian vein
effort thrombosis) and forms of arterial TOS,10,13e15
the outcomes of treatment for NTOS in this unique
population have not been well characterized.
With the advent of comprehensive pitch-by-pitch
assessment, application of complex statistical ana-
lytics, and the availability of large public databases,
a wealth of detailed information is currently avail-
able regarding baseball pitching performance at
the professional level.16e21 This information has
been used to evaluate the success rates and out-
comes of treatment for other conditions, such as
reconstruction of the medial ulnar collateral liga-
ment, yielding new insights into the value, and lim-
itations of surgical treatment.22e26 The purpose of
this study was to utilize objective performance met-
rics for Major League Baseball (MLB) pitchers who
have undergone surgical treatment for NTOS, to




Professional MLB pitchers who underwent surgical
treatment for NTOS between July 2001 and July
2014 were identified from publicly available media
and MLB team injury reports. Position players with
NTOSwere excluded from analysis, as were pitchers
who had undergone surgical treatment for either
arterial or venous forms of TOS. Of 13 MLB pitchers
meeting these criteria, 3 individuals didnot achieve a
sustained return to play at theMLB level after surgi-
cal treatment for NTOS. The study group thereby
consisted of 10 individuals meeting the inclusion
criteria and achieving a sustained return to MLB
before October 2015. The study was determined to
be exempt from full Institutional Review Board
(IRB) review by the Washington University School
of Medicine Human Research Subjects Committee.
Sources of Data
For each study subject, individual game logs for
MLB regular season games were compared from 2
independent sources to ensure data accuracy, Fan-
Graphs (http://www.fangraphs.com) and Brooks
Baseball (Pitch Info LLC, Chicago, IL; http://www.
brooksbaseball.net), with additional data obtained
from Baseball Reference (http://www.baseball-
reference.com).
Traditional Pitching Metrics
Fifteen traditional pitching metrics thought to be
potentially affected byNTOSwere selected for inclu-
sion in the study, including wineloss percentage,
strikeouts per 9 innings, walks per 9 innings (BB/
9), strikeouts per walks (SO/BB), home runs per 9
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innings, walks per batter faced, line drives per batter
faced, walks plus hits per inning pitched (WHIP),
strikeouts per batter faced, home runs per batter
faced, home runs per flyballs plus line drives,
ground ball per batter faced, fly balls per batter
faced, earned run average (ERA), fielding indepen-
dent pitching (FIP), ball percentage (B%), and strike
percentage (Str%).
Advanced Pitching Metrics
Beginning in2006, thePitchF/x system(Sportvision,
Chicago, IL) has tracked velocity, movement, spin
rate, spin direction, and other parameters on all
pitches at the MLB level. Pitch classifications within
the PitchF/x system are based on a real-time auto-
mated neural network algorithm, but automated
classifiers can have difficultywith certain pitch types
and pitches within a player’s skill set. Brooks Base-
ball reports pitch classification data that Pitch Info
LLC manually reviews for each pitcher and are
confirmed by other sources including video analysis
and on-field personnel. Pitch classifications used in
this analysis included grouped pitch types (hard, off-
speed, and breaking) and individual pitch types
(fourseam fastball, sinker, changeup, curveball, cut-
ter, and split-finger). The PitchF/x metrics used for
analysis in this study included average pitch velocity
(AvgV), maximum pitch velocity (MaxV), horizon-
tal movement, vertical movement, vertical move-
ment plus gravity effects, grooved pitch percentage,
whiff percentage, opponents isolated percentage,
swing percent, whiffs per swing, line drives per ball
in play, ground balls per ball in play, fly balls per
ball in play, opponent batting average, andopponent
slugging percentage.
Time-Period Scenarios for Analysis
For each study subject, individual career data for
traditional pitching metrics were initially compared
from before and after the time of surgical treatment.
As NTOS presents over shorter periods of time that
may not be reflected by career data, we next exam-
ined traditional and advanced pitching metrics for
the 3 years surrounding the index (surgical treat-
ment) year. For more detailed analysis closer to
the time of surgery, we then examined traditional
and advanced pitching metrics to compare 5
different time periods before the last game played
prior to surgery (4 weeks, 8 weeks, 12 weeks,
6 months, and 12 months) and the same 5 different
time periods after the first game back to pitching in
an official MLB game.
Statistical Methods
All statistical analyses were performed using SPSS
version 22 (IBMCorporation, Armonk, NY) or Prism
6.0 (GraphPad Software, Inc., La Jolla, CA). For
before-and-after surgery comparisons, paired
average performance data were analyzed by paired
t-tests for normally distributed data and by
Wilcoxon matched-pairs signed-rank tests for data
that were not normally distributed. Unpaired data
were analyzed using the nonparametric Manne
Whitney U-test. Multiple-group analyses were per-
formed using the nonparametric KruskaleWallis
analysis of variance test. For all tests, a P value
Table I. MLB pitchers with NTOS, careers before surgical treatment
Pitcher Side Age at debut
Career in MLB before surgery
Days Games Innings Pitches
1 Left 24 4485 587 2242 31,039
2 Left 22 381 26 147 2439
3 Right 23 103 9 52 841
4 Right 25 3075 358 363 5818
5 Right 25 3213 159 890 13,473
6 Right 21 4327 315 1937 29,344
7 Right 23 2869 188 994 15,294
8 Right 24 2611 308 333 4862
9 Left 24 2028 147 771 12,248
10 Left 21 2191 106 594 9449
Mean ± SEM 23 ± 1 2528 ± 457 220 ± 55 832 ± 232 12,481 ± 3309
Median 23.5 2740 174 683 10,849
SEM, standard error of the mean.
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<0.05 was considered to indicate a statistically
significant difference.
RESULTS
The 10 pitchers included in the study had a mean
age of 23.2 ± 0.5 years at first MLB appearance
and 6.9 ± 1.3 years of playing time before treatment
for NTOS, which occurred at a mean age of
30.2 ± 1.4 years (Table I). Figure 1 illustrates the
overall career timelines for this cohort in relation
to the time of surgery for NTOS, demonstrating a
mean interval between the last MLB appearance
and surgical treatment of 4.5 ± 2.3 months and a
mean period of postoperative rehabilitation to the
Table II. MLB pitchers with NTOS, careers after surgical treatment
Pitcher Age at surgery Rehab days
Career after return to MLB
Current statusDays Games Innings Pitches
1 36 246 2357 206 1253 19,940 Retired
2 23 260 1934 109 521 8860 Retired
3 23 281 862 72 446 7118 MLB
4 34 167 533 50 43 717 Retired
5 34 306 562 64 288 4865 MLB
6 33 273 116 20 115 1895 Retired
7 31 636 66 7 35 551 MLB
8 31 258 436 79 70 1107 MLB
9 30 509 109 23 42 671 MLB
10 27 315 141 20 129 1796 MLB
Mean ± SEM 30 ± 1 325 ± 44 712 ± 254 65 ± 19 294 ± 120 4752 ± 1926
Median 31.0 277 485 57 122 1846
SEM, standard error of the mean.
Fig. 1. Career timelines related to surgery for NTOS.
Career timelines are shown as horizontal bars for 10
MLB pitchers in relation to surgical treatment for
NTOS, from the first MLB appearance (debut) to the
end of 2015. The surgical treatment interval is divided
into the ‘‘preop’’ period (the interval between the last
MLB game appearance and surgical treatment) and the
‘‘rehab’’ period (the interval between surgical treatment
and the first MLB game appearance following surgery).
Mean ± SEM values (months) are shown for each inter-
val in the key (bordered inset). Current MLB playing status
as of October 2015 for each pitcher is designated as
retired (R) or active (A). SEM, standard error of the
mean.
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Fig. 2. Traditional pitching metrics, career. Nine relevant
traditional pitching performance metrics for 10 MLB
pitchers, comparing careers before and after surgical
treatment for NTOS. Data shown illustrate the individual
pitchers (open circles and line graphs) and group
mean ± SEM (shaded bar graphs with mean values
indicated). Solid horizontal lines to the right of each panel
indicate the 20-year MLB average for each metric (based
on 180 innings pitched per year). There were no signifi-
cant differences for any of the preop versus postop com-
parisons shown (Wilcoxon matched-pairs signed-rank
tests). SEM, standard error of the mean.
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first MLB reappearance of 10.8 ± 1.5 months.
Following the return after surgical treatment, the
pitchers in this cohort continued to play at themajor
league level for a mean of 2.0 ± 0.7 years, with 6
remaining active in MLB at the close of the study
period and the other 4 individuals having retired
due to factors or injuries unrelated to NTOS.
(Table II).
Analysis of pitching performance metrics was
conducted in 3 separate stages. First, data were
compared between the preoperative and postoper-
ative career periods for the cohort of pitchers
returning to MLB after surgery for NTOS. As
illustrated in Figure 2, this revealed no significant
differences with regard to 15 traditional pitching
metrics, including ERA, FIP, WHIP, BB/9, and
SO/BB.
In the second stage of analysis, data were exam-
ined for the 3 years before and the 3 years after
the return to MLB from surgical treatment. This
also revealed that there were no significant differ-
ences in traditional pitching metrics when
compared with the 2 time periods (Fig. 3). A com-
plete summary of traditional and advanced pitching
metrics for the 10 individual pitchers, for the 3 years
surrounding the index (surgical treatment) year, is
Fig. 3. Traditional pitching metrics, 3 years surrounding
index year. Twelve relevant traditional pitching perfor-
mance metrics for 10 MLB pitchers, comparing the
3 years before and after the index (surgical treatment)
year for NTOS. Data shown illustrate the mean ± SEM
for the group at each year surrounding the index year.
For each year, the number of evaluable individuals was
8 (Index  3), 8 (Index  2), 8 (Index  1), 7 (Index),
9 (Index + 1), 7 (Index + 2), and 3 (Index + 3). Solid hor-
izontal lines to the right of each panel indicate the 20-year
MLB average for each metric (based on 180 innings
pitched per year). There were no significant differences
for any of the comparisons shown (KruskaleWallis anal-
ysis of variance tests). SEM, standard error of the mean.
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presented in the Appendix. Figure 4 presents data
for 4 relevant PitchF/x advanced pitch metrics, for
which there were no significant differences.
In the third stage of analysis, performance data
were examined for 25 different time-period scenarios
surrounding the time of surgical treatment to
compare 72 advanced performance metrics (in total,
approximately 1800 time-period scenarios and per-
formance metrics were used as variables for
analysis). By using paired t-tests and Wilcoxon
matched-pairs signed-rank tests, there were a total
of 247 significant relationships detected among the
permutations analyzed. The data shown in Table III
indicate the number of significant relationships
detected for different time-period scenarios, with
the 8- to 12-week scenario having the highest num-
ber (18, 25%of the 72metrics analyzed). In assessing
the specific performancemetrics for the8- to12-week
time-period scenario, 54 of the 72 metrics (75%)
analyzed were unchanged (including ERA, WHIP,
and SO/BB). Fourteen metrics (19%) with a signifi-
cant difference represented an improvement in pitch-
ing performance after the return from surgical
treatment and 4 of the 18 metrics (6%) represented
a decline in pitching performance (Table IV). One of
these metrics that might be particularly relevant to
pitching performance was hard pitch maximum ve-
locity, where direct analysis of the 8- to 12-wk time-
period scenario revealed a decline from 93.1 ± 1.0
miles/hr before surgery to 92.5 ± 0.9 miles/hr after
surgery (P ¼ 0.047, Wilcoxon matched-pairs signed-
rank test). Data shown in Figure 5 illustrate that these
beforeeafter differences were considered significant
for only 3 of the 9 pitchers (3, 4, and 8), whereas
the comparisons for pitchers 2, 5, 6, 7, 9, and
10 were not significantly different (ManneWhitney
U-tests).
DISCUSSION
In this study, we utilized analysis of traditional and
advanced pitching performance metrics for a series
of professional baseball pitchers returning to MLB
after surgery for NTOS. The results demonstrate
that this cohort exhibited postoperative pitching
performance capabilities largely equivalent to or
better than those exhibited before surgical treat-
ment. This provides the first such evidence that
thoracic outlet decompression, along with an ample
period of postoperative rehabilitation, can provide
effective treatment for professional baseball pitchers
with career-threatening NTOS.
While this study represents the first analysis of
professional baseball pitchers that have returned to
MLB after treatment for NTOS, it remains limited
Fig. 4. Pitch velocity and movement metrics, 3 years sur-
rounding index year. Four relevant PitchF/x advanced
pitch metrics for 9 MLB pitchers, comparing the 3 years
before and after the index (surgical treatment) year for
NTOS. Data shown illustrate the mean ± SEM for the
group at each year surrounding the index year. For
each year, the number of evaluable individuals was 7
(Index  3), 7 (Index  2), 7 (Index  1), 6 (Index), 8
(Index + 1), 6 (Index + 2), and 2 (Index + 3). There
were no significant differences for any of the compari-
sons shown (KruskaleWallis analysis of variance tests).
SEM, standard error of the mean.
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by the small number of subjects available for anal-
ysis. Only 10 of the 13 pitchers (77%) who have un-
dergone surgical treatment for NTOS exhibited a
successful return to play at the MLB level for which
there were appropriate data available, so the study
group was necessarily biased toward those with suc-
cessful outcomes from surgery. It is not known why
other individuals did not achieve a return to MLB,
or if this was related to NTOS or other factors. In
addition, it is not entirely clear why the individuals
who retired during the study period chose to end
their MLB careers despite an apparently successful
return from surgery for NTOS. Another limitation
is the lack of information on additional injuries
that might have affected individual pitchers and
thereby influenced their performance, beyond any
limitations that might be attributed to NTOS.
The small number of pitchers described in this
study undoubtedly reflects the relatively rare
occurrence of NTOS compared with other condi-
tions more frequently affecting MLB pitchers, such
as shoulder or ulnar collateral ligament injuries, as
well as the difficulty in diagnosis and possible reluc-
tance to consider surgical treatment for NTOS in
elite athletes. The majority of the individuals in
this study (8 of 10) underwent surgical treatment af-
ter 2010, suggesting that there has been increasing
recognition of NTOS and appreciation for the poten-
tial benefits of surgical treatment. It remains unclear
if this might also reflect an actual increase in the
prevalence of NTOS in elite athletes, but this is
possible given the rigor of contemporary sports
training, high performance expectations, and the
frequency of upper extremity injury.
This study is unique with regard to the approach
used to assess surgical outcomes. Measures used to
evaluate results of treatment for NTOS are usually
semiquantitative patient-reported assessments of
Table III. Summary results for advanced pitching performance metrics, other time-period scenarios
Time period before
leave for surgery
Time period after return
from surgery Abbreviation used
Number of significant
relationships observed
12 months 4 weeks 12 months to 4 weeks 4
12 months 8 weeks 12 months to 8 weeks 7
12 months 12 weeks 12 months to 12 weeks 11
12 months 6 months 12 months to 6 months 9
12 months 12 months 12 months to 12 months 9
6 months 4 weeks 6 months to 4 weeks 8
6 months 8 weeks 6 months to 8 weeks 11
6 months 12 weeks 6 months to 12 weeks 14
6 months 6 months 6 months to 6 months 8
6 months 12 months 6 months to 12 months 8
12 weeks 4 weeks 12 weeks to 4 weeks 10
12 weeks 8 weeks 12 weeks to 8 weeks 17
12 weeks 12 weeks 12 weeks to 12 weeks 16
12 weeks 6 months 12 weeks to 6 months 12
12 weeks 12 months 12 weeks to 12 months 11
8 weeks 4 weeks 8 weeks to 4 weeks 10
8 weeks 8 weeks 8 weeks to 8 weeks 14
8 weeks 12 weeks 8 weeks to 12 weeks 18
8 weeks 6 months 8 weeks to 6 months 10
8 weeks 12 months 8 weeks to 12 months 10
4 weeks 4 weeks 4 weeks to 4 weeks 6
4 weeks 8 weeks 4 weeks to 8 weeks 5
4 weeks 12 weeks 4 weeks to 12 weeks 6
4 weeks 6 months 4 weeks to 6 months 6
4 weeks 12 months 4 weeks to 12 months 6
Twenty-five different time-period scenarios were selected for detailed analysis of beforeeafter surgery comparisons of 72 advanced
performance metrics for 9 MLB pitchers undergoing surgical treatment for NTOS (in total, approximately 1800 time-period
scenarios and performance metrics were used as variables for analysis). By paired t-tests and Wilcoxon matched-pairs signed-rank
tests, there were a total of 247 significant relationships detected among the permutations analyzed. The data shown indicate the
number of significant relationships detected for different time-period scenarios, with the 8- to 12-week scenario having the highest
number (18, 25% of the 72 metrics analyzed).
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pain and functional disability, which can be rela-
tively subjective as well as highly variable.4e6 The
abundance of objective performance measures
available in professional baseball thereby allows an
opportunity to assess the sport-specific outcomes
of surgery for NTOS in a manner independent of
subjective symptoms. Professional baseball pitchers
are certainly not typical of patients with NTOS,
without having had the magnitude or duration of
disability often exhibited by those with this condi-
tion, and the outcomes in professional baseball
pitchers cannot be extrapolated to other populations
of patients. Nonetheless, NTOS in an MLB pitcher is
a career-threatening development as it prevents
satisfactory performance and does not respond
well to conservative therapy. Thus, an important
conclusion from this study is that successful out-
comes can still be achieved with surgical treatment
for NTOS, even in a patient population with partic-
ularly demanding occupational requirements.
It is valuable in considering the findings of this
study to distinguish between the various statistical
metrics and how they might reflect different aspects
of baseball pitching performance following surgical
treatment. For example, ‘‘counting’’ metrics (e.g.,
G, IP) largely reflect playing opportunity and pitcher
durability and ‘‘aggregate’’ metrics (e.g., HR)
depend on opponent performance, whereas
‘‘descriptive’’ metrics (e.g., AvgV, MaxV) most
directly reflect health and level of performance
and ‘‘rate’’ metrics (e.g., SO%, WHIP) more closely
reflect pitching skill and effectiveness. Metrics that
depend on opponent hits or runs are thereby unsat-
isfactory in evaluating pitching recovery and perfor-
mance, and it is more valuable to emphasize metrics
that are under themore direct control of the pitcher.
Pitching performance metrics may also be separated
into those that assess throwing strength (pitch ve-
locity) and those that assess fine neurological motor
function (pitch control), because velocity and con-
trol may return at different phases of recovery
from surgery. Furthermore, some of the metrics
assessed here predominantly reflect the style of an
individual pitcher rather than talent or perfor-
mance. For example, the proportion of fly balls
versus ground balls reveals the general tendencies
of hitters against a given pitcher, based on the types
of pitches thrown and different game situations, and
Table IV. Significant relationships for the 8- to 12-week time-period scenario





Eight week to twelve week
difference P value
All FB/BF 0.25 ± 0.02 0.23 ± 0.03 0.03 ± 0.01 0.047a
All GB/BF 0.32 ± 0.03 0.36 ± 0.03 0.03 ± 0.01 0.040a
Hard MaxV 93.12 ± 1.03 92.50 ± 0.93 0.62 ± 0.23 0.025b
Hard OBA 0.303 ± 0.014 0.265 ± 0.021 0.04 ± 0.01 0.007a
Breaking FB/BIP 23.29 ± 3.81 10.42 ± 3.22 12.87 ± 3.69 0.008a
Breaking GB/BIP 33.26 ± 5.73 43.09 ± 6.96 9.83 ± 2.88 0.009a
Breaking HorzM 3.41 ± 1.26 4.08 ± 1.25 0.67 ± 0.21 0.015a
Breaking OBA 0.226 ± 0.028 0.167 ± 0.019 0.06 ± 0.02 0.023a
Breaking OSLG 0.343 ± 0.047 0.229 ± 0.029 0.11 ± 0.03 0.002a
Sinker Wf/Sw 5.08 ± 0.28 3.57 ± 0.45 3.64 ± 1.40 0.040b
Sinker MaxV 92.93 ± 0.99 92.31 ± 0.97 0.62 ± 0.17 0.011b
Sinker FB/BIP 18.83 ± 1.80 11.57 ± 2.84 7.27 ± 2.07 0.013b
Sinker OBA 0.336 ± 0.040 0.228 ± 0.036 0.11 ± 0.03 0.012a
Sinker OSLG 0.521 ± 0.035 0.347 ± 0.045 0.11 ± 0.03 0.012a
Curveball GB/BIP 27.95 ± 8.01 41.09 ± 7.15 13.15 ± 5.15 0.038a
Curveball HorzM 2.39 ± 1.36 3.10 ± 1.44 0.71 ± 0.29 0.042a
Curveball OBA 0.192 ± 0.041 0.123 ± 0.034 0.07 ± 0.02 0.014a
Slider VertM + G 39.27 ± 2.04 36.36 ± 2.17 2.91 ± 0.44 0.022a
Specific advanced performance metrics exhibiting significant differences in analysis of the 8- to 12-week time-period scenario for 9
MLB pitchers undergoing surgical treatment for NTOS. Fifty-four of 72 metrics (75%) analyzed were unchanged (not shown,
including ERA, WHIP, and SO/BB). Fourteen metrics (19%) with a significant difference represented an improvement in pitching
performance after the return from surgical treatment for NTOS. Four of the 18 metrics (6%) with a significant difference
represented a decline in pitching performance.
FB/BF, flyball per batter faced; FB/BIP, flyball per ball in play; GB/BF, groundball per batter faced; GB/BIP, groundball per ball in play;
HorzM, horizontal movement (inches); MaxV, maximum velocity (miles/hr); OBA, opponent batting average; OSLG, opponent
slugging percentage; SEM, standard error of the mean; VertM + G, vertical movement plus gravity (inches); Wf/Sw, whiff per swing.
aDifference designates improved pitching performance.
bDifference designates diminished pitching performance.
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Fig. 5. Individual comparisons of hard pitch maximum
velocity for the 8- to 12-week time-period scenario.
Hard pitch maximum velocity (PitchF/x advanced
pitch metrics) for 9 MLB pitchers, in direct analysis of
the 8- to 12-week time-period scenario. Data shown
illustrate the mean ± SEM maximum velocity for each
pitcher along with the number of games played and
innings pitched during each interval. The beforeeafter
differences were considered significant for 3 of the 9
pitchers (3, 4, and 8), whereas comparisons for the
remaining pitchers (2, 5, 6, 7, 9, and 10) were not signif-
icantly different (ManneWhitney U-tests). SEM, stan-
dard error of the mean.
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may not provide insight into the level of skill or
pitching performance. Indeed, pitcher style may
change over time and some may choose to change
their pitching repertoire during the course of their
careers. Finally, baseball organizations often use ag-
ing curves to predict the decline or rise of player per-
formance over time. While pitching performance is
expected to diminish with age, players who have
been able to return to the same level of performance
after a long period of recovery from surgery may
actually be considered to be improved given their
concomitant increase in age. These factors will all
be useful considerations for future research.
One of the most valuable insights from this study
is the apparent importance of gradual recovery and
postoperative rehabilitation, with most pitchers
requiring close to a year after surgery to return to
game-ready MLB performance. This is similar to the
recovery period expected for MLB pitchers undergo-
ing ulnar collateral ligament reconstruction, where
attempts to recover more rapidly can be predicted
to have less successful outcomes and a higher rate
of recurrent injury.22e26 Many of the individuals in
this study appear likely to have had some degree of
NTOS symptoms for one ormore seasons before diag-
nosis, along with multiple forms of treatment and
previous operations,without addressing the underly-
ing source of disability. These pitchersmay have tried
to play through considerable symptoms without suc-
cess, with surgery for NTOS undertaken only as a
‘‘last resort’’ before considering retirement. While
the inciting cause of chronic brachial plexus
compression injury may be alleviated by thoracic
outlet decompression, neural healing is an extremely
slow process that may only begin once decompres-
sion is accomplished. Furthermore, patients with
longstanding NTOS develop compensatory alter-
ations in posture and shoulder girdle mechanics to
minimize brachial plexus nerve irritation. These ad-
aptationsmay cause additional secondary symptoms,
such as sustained spasm in the rhomboid, trapezius,
and posterior neck muscles. Because surgical treat-
ment for NTOS does not necessarily alter chronic
neural injury or compensatory alterations, physical
therapy remains a crucial part of recovery to retrain
associated muscle groups and to improve shoulder
girdle biomechanics. This is likely another major
reason that recovery from surgery for NTOS can
take much longer than might be expected, a factor
likely to be magnified in MLB pitchers.
This study suggests a number of directions for
future research. While there have been similar
studies on MLB pitchers examining return to play
and performance metrics after ulnar collateral liga-
ment repair, investigators have also begun to
examine specific alterations in pitching biome-
chanics in pitchers who have undergone such oper-
ations.27,28 It would therefore be of interest to
examine if pitchers recovered from surgery for
NTOS have any consistent or sustained alterations
in shoulder girdle or throwing biomechanics. There
have also been attempts to identify sabermetric pa-
rameters or profiles associated with subsequent
injury or time on the disabled list due to shoulder
or elbow injuries, raising the possibility that there
might be similar sabermetric profiles of pitchers at
risk for developing NTOS.29e31 Finally, it is notable
that the subjects of this study typically underwent
surgery for NTOS after a period of declining perfor-
mance and a protracted search for diagnosis, which
may have adversely affected recovery from surgery.
It remains possible that with earlier diagnosis and
prompt surgical treatment, more rapid recovery
and rehabilitation may be feasible than observed
in the present cohort. Efforts to provide earlier diag-
nosis of NTOS, such as with exercise-enhanced
scalene muscle anesthetic blocks,32,33 may help
improve results from physical therapy, use of alter-
native approaches (e.g., scalene muscle injections
with botulinum toxin),34,35 or different forms of
surgical treatment.36
CONCLUSIONS
Based on the analysis of traditional and advanced
pitching metrics, the performance of professional
baseball pitchers who returned toMLB after surgery
for NTOS was similar to their performance before
treatment. Thoracic outlet decompression and
postoperative rehabilitation can provide effective
treatment for professional baseball pitchers with
career-threatening NTOS.
This work was supported by the Thoracic Outlet Syndrome
Research and Education Fund of the Barnes-Jewish Hospital
Foundation, St. Louis, MO.
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